Advance Search
Volume 38 Issue 7
Jul.  2022
Turn off MathJax
Article Contents
XU Ying-hua, LI Ya-nan, YE Qiang. Current status and challenges of meningococcal vaccines development in China[J]. Chinese Journal of Public Health, 2022, 38(7): 948-951. doi: 10.11847/zgggws1136615
Citation: XU Ying-hua, LI Ya-nan, YE Qiang. Current status and challenges of meningococcal vaccines development in China[J]. Chinese Journal of Public Health, 2022, 38(7): 948-951. doi: 10.11847/zgggws1136615

Current status and challenges of meningococcal vaccines development in China

doi: 10.11847/zgggws1136615
  • Received Date: 2021-08-23
    Available Online: 2021-12-30
  • Publish Date: 2022-07-10
  • Vaccination is the most effective and economical way to prevent meningococcal meningitis. In the past few decades, with widespread use of meningococcal vaccines, the incidence of meningococcal meningitis has dropped significantly. There are some vaccines available in Chinese markets, of which mainly included groups A, C, W, and Y monovalent and multivalent polysaccharide meningococcal vaccines (MPV), group A and C polysaccharide meningococcal conjugated vaccines (MPCV-AC), and meningococcal groups A and C and haemophilus b conjugate vaccine (MPCV-AC-hib). With the nearly 50 years of development of meningococcal vaccines in China, significant achievements have been made in vaccine production, quality control, and related research, but the burden of meningococcal disease is still underestimated; the meningococcal vaccine immunization strategy has not been perfected; meningococcal vaccines from different manufacturers have inconsistent immunization procedures and no group B meningococcal vaccines are available in the market. Therefore, it is suggested that meningococcal monitoring methods should be continuously improved and research on meningococcal disease burden should be carried out for facilitating the improvement of meningococcal vaccine immunization procedures and strategy. Furthermore, considering the serogroup highly variable and antigen drift characteristics of Neisseria meningitides, a vaccine with longer immunity and better protection effect should be developed by using genetic recombination and other technologies.
  • loading
  • [1]
    Linder KA, Malani PN. Meningococcal meningitis[J]. JAMA, 2019, 321(10): 1014. doi: 10.1001/jama.2019.0772
    [2]
    杨俊峰, 李艺星, 尹遵栋, 等. 2004 — 2005年我国流行性脑脊髓膜炎病死率分析[J]. 中国公共卫生, 2006, 22(12): 1518 – 1519. doi: 10.11847/zgggws2006-22-12-65
    [3]
    Olbrich KJ, Müller D, Schumacher S, et al. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers[J]. Infectious Diseases and Therapy, 2018, 7(4): 421 – 438. doi: 10.1007/s40121-018-0213-2
    [4]
    Xu YH, Li YN, Wang SS, et al. Meningococcal vaccines in China[J]. Human Vaccines and Immunotherapeutics, 2021, 17(7): 2197 – 2204. doi: 10.1080/21645515.2020.1857201
    [5]
    国家卫生健康委. 2019年全国法定传染病疫情概况[R]. 北京: 国家卫生健康委, 2002.
    [6]
    国家卫生健康委. 2020年全国法定传染疫情概况[R]. 北京: 国家卫生健康委, 2021.
    [7]
    Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the poten-tial for prevention through vaccination[J]. Journal of Infection, 2020, 81(4): 483 – 498. doi: 10.1016/j.jinf.2020.05.079
    [8]
    Pan JR, Yao PP, Zhang H, et al. The case of a new sequence type 7 serogroup X Neisseria meningitidis infection in China: may capsular switching change serogroup profile?[J]. International Journal of Infectious Diseases, 2014, 29: 62 – 64. doi: 10.1016/j.ijid.2014.07.022
    [9]
    邵祝军, 徐丽, 高源, 等. 中国流行性脑脊髓膜炎流行菌群变化趋势分析[J]. 中国计划免疫, 2007, 13(6): 541 – 544. doi: 10.3969/j.issn.1006-916X.2007.06.008
    [10]
    Shao ZJ, Li W, Ren J, et al. Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China[J]. The Lancet, 2006, 367: 419 – 423. doi: 10.1016/S0140-6736(06)68141-5
    [11]
    李军宏, 吴丹, 温宁, 等. 2015 — 2019年中国流行性脑脊髓膜炎血清群分布特征[J]. 中国疫苗和免疫, 2020, 26(3): 241 – 244.
    [12]
    赵盼, 朱兵清, 张艾煜, 等. 中国脑膜炎奈瑟菌ST-4821克隆群荚膜基因簇分布特征[J]. 疾病监测, 2020, 35(6): 508 – 512. doi: 10.3784/j.issn.1003-9961.2020.06.011
    [13]
    国家卫生健康委. 国家卫生健康委关于印发国家免疫规划疫苗儿童免疫程序及说明 (2021年版) 的通知[EB/OL]. (2021 – 03 – 12)[2021 – 08 – 10]. http://www.nhc.gov.cn/jkj/s3581/202103/590a8c7915054aa682a8d2ae8199e222.shtml.
    [14]
    柴志凯, 李军, 邵祝军, 等. 流行性脑脊髓膜炎监测与免疫预防专家研讨会会议纪要[J]. 中国预防医学杂志, 2015, 16(12): 901 – 903.
    [15]
    Weintraub A. Immunology of bacterial polysaccharide antigens[J]. Carbohydrate Research, 2003, 338(23): 2539 – 2547. doi: 10.1016/j.carres.2003.07.008
    [16]
    赵东阳, 谢志强, 苟锦博, 等. 3月龄婴儿接种A群C群脑膜炎球菌多糖结合疫苗的免疫原性和不良反应[J]. 中国疫苗和免疫, 2020, 26(4): 387 – 390.
    [17]
    [18]
    Kurosky SK, Davis KL, Krishnarajah G. Effect of combination vaccines on completion and compliance of childhood vaccinations in the United States[J]. Human Vaccines and Immunotherapeutics, 2017, 13(11): 2494 – 2502. doi: 10.1080/21645515.2017.1362515
    [19]
    Klein NP, Abu-Elyazeed R, Baine Y, et al. Immunogenicity and safety of the Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants[J]. Human Vaccines and Immunotherapeutics, 2019, 15(2): 327 – 338. doi: 10.1080/21645515.2018.1526586
    [20]
    李亚南, 梁丽, 李艳萍, 等. A、C群脑膜炎球菌 – b型流感嗜血杆菌多糖结合疫苗免疫学效果观察[J]. 中国生物制品学杂志, 2012, 25(9): 1190 – 1194,1197.
    [21]
    李江嵘, 杨军, 刘晓强, 等. AC群脑膜炎球菌 (结合) b型流感嗜血杆菌 (结合) 联合疫苗上市后2~71月龄儿童接种的安全性研究[J]. 中国疫苗和免疫, 2016, 22(5): 578 – 581.
    [22]
    Li YX, Yin ZD, Shao ZJ, et al. Population-based surveillance for bacterial meningitis in China, September 2006 – December 2009[J]. Emerging Infectious Diseases, 2014, 20(1): 61 – 69.
    [23]
    吴丹, 李艺星, 邵祝军, 等. 2006 — 2013年中国4个城市急性脑膜炎脑炎流行病学疾病负担研究[J]. 中华预防医学杂志, 2019, 53(2): 164 – 168.
    [24]
    邵祝军. 流行性脑脊髓膜炎流行现状及防控形势[J]. 中华预防医学杂志, 2019, 53(2): 129 – 132.
    [25]
    中华预防医学会. 脑膜炎球菌疫苗的有效性、安全性和成本效益研究进展[J]. 中华流行病学杂志, 2019, 40(2): 129 – 135. doi: 10.3760/cma.j.issn.0254-6450.2019.02.002
    [26]
    李军宏, 李艺星, 吴丹, 等. 中国2006 — 2014年流行性脑脊髓膜炎病例菌群分布特征及变迁趋势[J]. 中国疫苗和免疫, 2015, 21(5): 481 – 485.
    [27]
    吴疆. 中国脑膜炎球菌疫苗预防接种专家共识[J]. 中华预防医学杂志, 2019, 53(2): 141 – 145.
    [28]
    Parikh SR, Newbold L, Slater S, et al. Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment[J]. The Lancet Infectious Diseases, 2017, 17(7): 754 – 762. doi: 10.1016/S1473-3099(17)30170-6
    [29]
    Ostergaard L, Lucksinger GH, Absalon J, et al. A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults[J]. Vaccine, 2016, 34(12): 1465 – 1471. doi: 10.1016/j.vaccine.2016.01.044
    [30]
    朱兵清, 高婉迎, 徐丽, 等. 中国B群脑膜炎奈瑟菌分子流行病学特征分析[J]. 中华预防医学杂志, 2019, 53(2): 153 – 158.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Article views (311) PDF downloads(54) Cited by()
    Proportional views

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return